---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-23-000722"
form_type: "8-K"
ticker: "ALDX"
cik: "0001341235"
company_name: "Aldeyra Therapeutics, Inc."
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T21:16:55.707931+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Aldeyra Q1 net loss $15.6M; PDUFA dates set; clinical readouts in Q2 2023

## Summary
- Net loss $15.6M ($0.27 loss per share) vs $16.8M ($0.29) in Q1 2022.
- Cash and equivalents $165.0M; projected runway into H2 2024.
- PDUFA dates: ADX-2191 (June 21, 2023) for vitreoretinal lymphoma; reproxalap (Nov 23, 2023) for dry eye.
- Top-line Q2 2023: Phase 2 ADX-2191 (retinitis pigmentosa), Phase 2 ADX-629 (chronic cough), Phase 3 INVIGORATE-2 (allergic conjunctivitis).
- Aldeyra will discontinue quarterly earnings conference calls, citing shift to clinical/regulatory updates.

## SEC filing metadata
- accession: 0001157523-23-000722
- form_type: 8-K
- ticker: ALDX
- cik: 0001341235
- company_name: Aldeyra Therapeutics, Inc.
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1341235/000115752323000722/0001157523-23-000722-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1341235/000115752323000722/a53393376.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-23-000722
- JSON: https://secwatch.observer/filing/0001157523-23-000722.json
- Plain text: https://secwatch.observer/filing/0001157523-23-000722.txt

## Key facts
- Earnings Releases
  Aldeyra Therapeutics, Inc. reported financial results for the quarter ended March 31, 2023.
  - Period: the quarter ended March 31, 2023
  - Result: reported results
  source text: On May 4, 2023, Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) issued a press release (the “Press Release”) regarding its financial results for the quarter ended March 31, 2023 and recent corporate highlights.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1341235/000115752323000722/0001157523-23-000722-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.